Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Roles of the EZH2 histone methyltransferase in cancer epigenetics

(2008) Jeffrey A. Simon et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

(2008) Yutaka Kondo et al.   NATURE GENETICS